291 related articles for article (PubMed ID: 23485939)
1. Virological response and antiviral resistance mutations in chronic hepatitis B subjects experiencing entecavir therapy: an Indian subcontinent perspective.
Ismail AM; Sharma OP; Kumar MS; Eapen CE; Kannangai R; Abraham P
Antiviral Res; 2013 May; 98(2):209-16. PubMed ID: 23485939
[TBL] [Abstract][Full Text] [Related]
2. Dynamics of hepatitis B virus resistance substitutions correlates with virological response in lamivudine-refractory patients with entecavir rescue monotherapy.
Zhang Y; He S; Li QL; Guo JJ
Virus Res; 2013 Nov; 177(2):156-62. PubMed ID: 23968804
[TBL] [Abstract][Full Text] [Related]
3. Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety.
Yuen MF; Seto WK; Fung J; Wong DK; Yuen JC; Lai CL
Am J Gastroenterol; 2011 Jul; 106(7):1264-71. PubMed ID: 21364549
[TBL] [Abstract][Full Text] [Related]
4. Evolutionary patterns of hepatitis B virus quasispecies under different selective pressures: correlation with antiviral efficacy.
Liu F; Chen L; Yu DM; Deng L; Chen R; Jiang Y; Chen L; Huang SY; Yu JL; Gong QM; Zhang XX
Gut; 2011 Sep; 60(9):1269-77. PubMed ID: 21292683
[TBL] [Abstract][Full Text] [Related]
5. Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years.
Wong GL; Wong VW; Chan HY; Tse PC; Wong J; Chim AM; Yiu KK; Chu SH; Chan HL
Aliment Pharmacol Ther; 2012 Jun; 35(11):1326-35. PubMed ID: 22506552
[TBL] [Abstract][Full Text] [Related]
6. Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients.
Ono A; Suzuki F; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Suzuki Y; Saitou S; Arase Y; Ikeda K; Kobayashi M; Watahiki S; Mineta R; Kumada H
J Hepatol; 2012 Sep; 57(3):508-14. PubMed ID: 22659518
[TBL] [Abstract][Full Text] [Related]
7. Profile of HBV antiviral resistance mutations with distinct evolutionary pathways against nucleoside/nucleotide analogue treatment among Chinese chronic hepatitis B patients.
Yang JX; Liu BM; Li XG; Yan CH; Xu J; Sun XW; Wang YH; Jiao XJ; Yan L; Dong JP; Hou CS; Abuduheilili X; Li T; Zhuang H
Antivir Ther; 2010; 15(8):1171-8. PubMed ID: 21149924
[TBL] [Abstract][Full Text] [Related]
8. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues.
Reijnders JG; Deterding K; Petersen J; Zoulim F; Santantonio T; Buti M; van Bömmel F; Hansen BE; Wedemeyer H; Janssen HL;
J Hepatol; 2010 Apr; 52(4):493-500. PubMed ID: 20185191
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of entecavir switch therapy in chronic hepatitis B patients with incomplete virological response to telbivudine.
Lo AO; Wong VW; Wong GL; Chan HY; Cheung CM; Chan HL
Antivir Ther; 2013; 18(5):671-9. PubMed ID: 23462214
[TBL] [Abstract][Full Text] [Related]
10. Complexity and diversity of hepatitis B virus quasispecies: correlation with long-term entecavir antiviral efficacy.
Tong J; Li QL; Huang AL; Guo JJ
Antiviral Res; 2013 Sep; 99(3):312-7. PubMed ID: 23832087
[TBL] [Abstract][Full Text] [Related]
11. HBV mutations associated with lamivudine therapy.
Lapiński TW; Parfieniuk-Kowerda A; Trzos A; Jaroszewicz J; Kowalczuk O; Nikliński J; Flisiak R
Przegl Epidemiol; 2013; 67(4):611-6, 705-8. PubMed ID: 24741905
[TBL] [Abstract][Full Text] [Related]
12. Do different lamivudine-resistant hepatitis B genotypes carry the same risk of entecavir resistance?
Lee GH; Aung MO; Dan YY; Lee YM; Mak B; Low HC; Lim K; Thwin MA; Tan PS; Lim SG
J Med Virol; 2013 Jan; 85(1):26-33. PubMed ID: 23023992
[TBL] [Abstract][Full Text] [Related]
13. Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir.
Pan CQ; Hu KQ; Yu AS; Chen W; Bunchorntavakul C; Reddy KR
J Viral Hepat; 2012 Mar; 19(3):213-9. PubMed ID: 22329376
[TBL] [Abstract][Full Text] [Related]
14. Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir.
Ong A; Wong VW; Wong GL; Chan HY; Tse CH; Chan HL
Aliment Pharmacol Ther; 2011 Oct; 34(8):972-81. PubMed ID: 21883327
[TBL] [Abstract][Full Text] [Related]
15. Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice.
Salpini R; Alteri C; Cento V; Pollicita M; Micheli V; Gubertini G; De Sanctis GM; Visca M; Romano S; Sarrecchia C; Andreoni M; Angelico M; Parruti G; Svicher V; Perno CF
J Med Virol; 2013 Jun; 85(6):996-1004. PubMed ID: 23588725
[TBL] [Abstract][Full Text] [Related]
16. [Entecavir resistance in entecavir naive lamivudine treated chronic hepatitis B patients].
Sayan M; Hülagü S; Akhan SC; Sentürk O; Meriç M; Cekmen M
Mikrobiyol Bul; 2009 Jul; 43(3):425-32. PubMed ID: 19795617
[TBL] [Abstract][Full Text] [Related]
17. Molecular characterization of a novel entecavir mutation pattern isolated from a multi-drug refractory patient with chronic hepatitis B infection.
Karatayli E; Karatayli SC; Cinar K; Gokahmetoglu S; Güven K; Idilman R; Yurdaydin C; Bozdayi AM
J Clin Virol; 2012 Feb; 53(2):130-4. PubMed ID: 22078148
[TBL] [Abstract][Full Text] [Related]
18. Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance.
Yang HJ; Lee JH; Kim YJ; Yoon JH; Lee HS
J Med Virol; 2012 Mar; 84(3):424-30. PubMed ID: 22246827
[TBL] [Abstract][Full Text] [Related]
19. [Clinical characteristics and effect of secondary individualized therapy in chronic hepatitis B patients infected with the rtA181 mutation hepatitis B virus].
Ji FZ; Wang L; Yang BH; Zhao JJ; Liu F; Xue Y; Li T
Zhonghua Gan Zang Bing Za Zhi; 2012 Apr; 20(4):280-4. PubMed ID: 22964149
[TBL] [Abstract][Full Text] [Related]
20. Antiviral efficacy of entecavir for hepatitis B virus rtA181V/T mutants.
Li P; Geng J; Li W; Xu X; Zhang X; Zheng W; Yu Y; Yang Z; Wang M
Virol J; 2017 Apr; 14(1):68. PubMed ID: 28376852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
